SSA
NTLA icon

Schonfeld Strategic Advisors’s Intellia Therapeutics NTLA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,600
Closed -$3.01M – 2367
2021
Q2 		$3.01M Buy
+18,600
New +$1.45M 0.03% 590

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Schonfeld Strategic Advisors's NTLA Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 75,244 shares — an estimated $676K sold.

Schonfeld Strategic Advisors first reported a position in NTLA in Q2 2016 and held it in 17 quarters. The position peaked at $4.17M in Q2 2024. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 75,244 Intellia Therapeutics shares in Q1 2026, an estimated $676K.
  • Schonfeld Strategic Advisors first reported a position in Intellia Therapeutics in Q2 2016 and held it in 17 quarters.
  • Schonfeld Strategic Advisors's Intellia Therapeutics position peaked at $4.17M in Q2 2024.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.